Physicians and health policy-makers alike have a responsibility to ensure, as use of GLP-1 medications continues to rise, that all young children with obesity who need these dr .
There are currently limited weight loss therapeutic options indicated for use in patients aged between six and 12 years old.
At a specialist childhood obesity clinic, almost all of the children are not in school.
Novo Nordisk (NVO) said Monday its phase 3 Step Young trial evaluating once-weekly semaglutide in children aged six to under 12 with obesity met its primary endpoint.
The Danish drugmaker said the clinical trial met its primary goal after 68 weeks of treatment.
Data highlights The STEP Young phase 3 trial met its primary endpoint, demonstrating greater body mass index (BMI) reduction in children aged 6 to under 12 treated with once-weekly subcutaneous .
Novo Nordisk (NYSE:NVO) said on Monday that 40.
The drug helped older kids lose weight in earlier studies but this marks the first trial looking at its effect on young children.
Novo Nordisk (NVO) stock dropped 1.
Kentucky has one of the highest childhood obesity rates in the country, and the health consequences carry forward throughout life.
Although the number of U.
Women who had a BMI trajectory for overweight or obesity during childhood are less likely to give birth beginning at age 25 years than women who had an average BMI trajectory, researchers reported in .